| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0014-2999(98)00851-6 |
| P698 | PubMed publication ID | 9988095 |
| P2093 | author name string | Navarro M | |
| Rodríguez de Fonseca F | |||
| Palomo T | |||
| Gorriti MA | |||
| P2860 | cites work | Cannabinoid receptor localization in brain | Q24558751 |
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats | Q28332347 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| Drug abuse: hedonic homeostatic dysregulation | Q29615904 | ||
| CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts | Q30049210 | ||
| Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. | Q34359201 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis | Q34631075 | ||
| Marijuana's interaction with brain reward systems: update 1991. | Q37028121 | ||
| Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. | Q37096501 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| Pharmacology of cannabinoid receptors | Q40437020 | ||
| Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal | Q40890918 | ||
| Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons | Q41048190 | ||
| Interaction between ?9-Tetrahydrocannabinol and d-amphetamine | Q41343834 | ||
| The effects of psychotropic drugs on exploratory and stereotyped behaviour of rats studied on a hole-board | Q41359462 | ||
| Modulation of neurotransmission by cannabinoids in the basal ganglia | Q41371378 | ||
| Cannabis and neuroleptic agents in schizophrenia | Q41535630 | ||
| Comparative effects of tetrahydrocannabinol on psychostimulant-induced behaviors | Q41536978 | ||
| Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas | Q42451556 | ||
| Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. | Q48183236 | ||
| Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment | Q48209713 | ||
| Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations | Q48272341 | ||
| Regional brain homovanillic acid following delta 9-tetrahydrocannabinol and cocaine | Q48376200 | ||
| Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. | Q48493259 | ||
| Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. | Q48631827 | ||
| Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines | Q48706445 | ||
| Life events-induced decrease of corticosteroid type I receptors is associated with reduced corticosterone feedback and enhanced vulnerability to amphetamine self-administration | Q48737775 | ||
| Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. | Q51106735 | ||
| An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. | Q51139556 | ||
| Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. | Q51608332 | ||
| Factors that predict individual vulnerability to amphetamine self-administration. | Q52266857 | ||
| Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up | Q57417862 | ||
| Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity | Q64386018 | ||
| Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. | Q64996366 | ||
| Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: Evidence of an acute effect and development of tolerance in chronic treatments | Q67651161 | ||
| The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study | Q69853528 | ||
| Positive and negative schizophrenic symptoms and the role of dopamine | Q70901580 | ||
| Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand | Q71040771 | ||
| Corticosterone elevation mediated centrally by Δ1-tetrahydrocannabinol in rats | Q71784463 | ||
| Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats | Q72021208 | ||
| Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study | Q72656516 | ||
| Repeated stimulation of D1 dopamine receptors enhances (-)-11-hydroxy-delta 8-tetrahydrocannabinol-dimethyl-heptyl-induced catalepsy in male rats | Q72682980 | ||
| Tetrahydrocannabinol potentiates reserpine-induced hypokinesia | Q72916142 | ||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| tetrahydrocannabinol | Q190067 | ||
| P304 | page(s) | 133-142 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats | |
| P478 | volume | 365 |
| Q44853701 | A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission |
| Q36741898 | A neuropeptide-centric view of psychostimulant addiction |
| Q55002265 | Adolescent THC exposure does not sensitize conditioned place preferences to subthreshold d-amphetamine in male and female rats. |
| Q44126671 | Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats |
| Q36938316 | Biological treatments for amfetamine dependence : recent progress |
| Q34616145 | Cannabinoid addiction: behavioral models and neural correlates. |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
| Q30807024 | Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data |
| Q59187306 | Cannabis and psychosis |
| Q34005782 | Cannabis and psychosis: what is the link? |
| Q82188891 | Cannabis consumption and risk of developing schizophrenia: myth or reality? |
| Q34549939 | Cannabis use and risk of psychosis: an etiological link? |
| Q45049153 | Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms |
| Q35104458 | Cholecystokinin modulation of mesolimbic dopamine function: regulation of motivated behaviour |
| Q50561525 | Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. |
| Q46425083 | Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain |
| Q43668148 | Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction |
| Q48109648 | Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats |
| Q30630783 | Cocaine-induced behavioral sensitization is associated with changes in the expression of endocannabinoid and glutamatergic signaling systems in the mouse prefrontal cortex. |
| Q28578568 | Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain |
| Q34575484 | Drug addiction. |
| Q34290364 | Drugs of abuse and increased risk of psychosis development. |
| Q37618728 | Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum |
| Q43698135 | Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation |
| Q46988493 | Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys |
| Q44845267 | Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade |
| Q55452539 | Endocannabinoids and Schizophrenia. |
| Q33899850 | Endogenous cannabinoid signaling and psychomotor disorders |
| Q46673452 | Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine |
| Q46652152 | Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice |
| Q44048463 | Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. |
| Q34257459 | Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys |
| Q46370479 | Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia |
| Q85159882 | Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251 |
| Q36259799 | Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence |
| Q27014154 | Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction |
| Q34721989 | Neurodevelopmental impairment, dopamine sensitisation, and social adversity in schizophrenia |
| Q51002104 | Neurotoxicity and substance abuse: further fuel for regulatory dilemma. |
| Q96953338 | One Is Not Enough: Understanding and Modeling Polysubstance Use |
| Q44535579 | Perinatal exposure to delta 9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats |
| Q37446838 | Pharmacological blockade of either cannabinoid CB1 or CB2 receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of cell proliferation in the hippocampus of adult male rat. |
| Q44371415 | Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. |
| Q38636791 | Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure |
| Q42598594 | Prenatal elevation of endocannabinoids corrects the unbalance between dopamine systems and reduces activity in the Naples High Excitability rats. |
| Q35713119 | Prenatal tetrahydrocannabinol (THC) alters cognitive function and amphetamine response from weaning to adulthood in the rat |
| Q35624218 | Pretreatment with Δ9-tetrahydrocannabinol (THC) increases cocaine-stimulated activity in adolescent but not adult male rats |
| Q48693573 | Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats |
| Q30500429 | Previous exposure to delta9-tetrahydrocannibinol enhances locomotor responding to but not self-administration of amphetamine |
| Q73704501 | Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor |
| Q34993855 | Role of cannabis and endocannabinoids in the genesis of schizophrenia |
| Q44865127 | Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia |
| Q57403357 | Schizophrenia and Substance Abuse Co-Morbidity |
| Q28216128 | Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1 |
| Q33507244 | Should burden of disease estimates include cannabis use as a risk factor for psychosis? |
| Q47591946 | System-specific activity in response to Δ9 -tetrahydrocannabinol: a functional magnetic resonance imaging study in awake male rats. |
| Q36508056 | Tardive dyskinesia and essential fatty acids |
| Q30047193 | The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis |
| Q33934278 | The endocannabinoid system as a target for therapeutic drugs. |
| Q34099000 | The endocannabinoid system: a physiological perspective on its role in psychomotor control |
| Q34786832 | The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. |
| Q29615356 | The molecular logic of endocannabinoid signalling |
| Q28280265 | The role of CB1 receptors in psychostimulant addiction |
| Q80286287 | [Cannabis use and risk of psychosis, an etiological link?] |
Search more.